Patent · US Active

Peptide diagnostic agent for lyme disease

US7887815B2 · kind B2 · utility

11Cited by
8References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 10, 2008
Grant dateFeb 15, 2011
Priority date
Expiry dateNov 10, 2028

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates, e.g., to an isolated peptide consisting of the sequence MKKDDQIAAAIALRGMA (SEQ ID NO:1) or an active variant thereof, wherein the peptide or active variant can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Also disclosed are linear multimeric peptides that contain the peptide represented by SEQ ID NO:1 as well as one or more additional peptide epitopes from other Borrelia proteins that can also bind specifically to an antibody as above. Compositions and diagnostic kits comprising a peptide of the invention are described, as are diagnostic assays using the peptide(s).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.